Neoadjuvant chemotherapy with biosimilar trastuzumab in human epidermal growth factor receptor 2 overexpressed non-metastatic breast cancer: patterns of use and clinical outcomes in India

BACKGROUND: Human epidermal growth factor receptor 2 (HER2)-positive breast cancer is associated with poor prognosis and access to anti-HER2 treatment is still a challenge in lower-middle income countries. The availability of the biosimilar trastuzumab has improved access by lowering the costs. We r...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Ecancermedicalscience
Main Authors: Joel, Anjana, Georgy, Josh Thomas, Thumaty, Divya Bala, John, Ajoy Oommen, Chacko, Raju Titus, Rebekah, Grace, Sigamani, Elanthenral, Chandramohan, Jagan, Manipadam, Marie Therese, Cherian, Anish Jacob, Abraham, Deepak Thomas, Jacob, Paul Mazhuvanchary, Sebastian, Patricia, Backianathan, Selvamani, Singh, Ashish
Formato: Artigo
Idioma:Inglês
Publicado em: Cancer Intelligence 2021
Assuntos:
Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8057782/
https://ncbi.nlm.nih.gov/pubmed/33912232
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3332/ecancer.2021.1207
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados